利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.01 秒)

    NANOPARTICLES DELIVERY SYSTEMS, PREPARATION AND USES THEREOF
    4.
    发明授权
    NANOPARTICLES DELIVERY SYSTEMS, PREPARATION AND USES THEREOF 有权

    公开(公告)号：EP2670394B1

    公开(公告)日：2018-11-21

    申请号：EP12702019.6

    申请日：2012-01-31

    申请人： Nanobiotix

    发明人： POTTIER, Agnès ,  LEVY, Laurent ,  MEYRE, Marie-Edith ,  GERMAIN, Matthieu

    IPC分类号： A61K9/127 ,  A61K9/51 ,  A61K49/00 ,  A61K49/18 ,  A61K41/00

    CPC分类号： A61K9/1271 ,  A61K9/5115 ,  A61K41/0028 ,  A61K49/0002 ,  A61K49/1812

    摘要： The invention pertains to thermosensitive liposomes encapsulating nanoparticles. In certain embodiments, the thermosensitive liposomes of the invention disrupt when heated at gel-to-liquid crystalline phase transition temperature (Tm) or above Tm, wherein the liposome comprises a thermosensitive lipidic membrane encapsulating nanoparticles. The nanoparticles used in the invention comprise an inorganic core the largest dimension of which is less than about 100 nm that is fully coated with an agent responsible for the presence of an electrostatic charge below −20 mV or above +20 mV at the surface of the nanoparticle, the electrostatic charge being determined by zeta potential measurements in an aqueous medium between pH 6 and 8, for a concentration of nanoparticles in suspension in the aqueous medium varying between 0.2 and 8 g/L. The invention also relates to pharmaceutical and diagnostic compositions comprising the thermosensitive liposomes as well as to their uses.

    PHARMACEUTICAL COMPOSITION, PREPARATION AND USES THEREOF
    5.
    发明公开
    PHARMACEUTICAL COMPOSITION, PREPARATION AND USES THEREOF 审中-公开
    药物组合物，制剂和用途

    公开(公告)号：EP3236934A1

    公开(公告)日：2017-11-01

    申请号：EP15798435.2

    申请日：2015-11-24

    申请人： Nanobiotix

    发明人： GERMAIN, Matthieu ,  MEYRE, Marie-Edith ,  POTTIER, Agnès ,  LEVY, Laurent

    IPC分类号： A61K9/00 ,  A61K41/00 ,  A61K9/127 ,  A61K47/50 ,  A61K51/12

    CPC分类号： A61K9/1271 ,  A61K9/0009 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/51 ,  A61K31/704 ,  A61K47/6911

    摘要： The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm and its absolute surface charge value is of at least 10 mV (|10 mV|). The carrier is in addition devoid of any surface sterically stabilizing agent. The invention also relates to such a composition for use for administering the pharmaceutical compound(s) in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one carrier comprising the at least one pharmaceutical compound are to be administered separately in a subject in need of said pharmaceutical compound, typically between more than 5 minutes and about 72 hours one from each other.

    摘要翻译： 本发明涉及药物组合物，其包含（i）至少一种生物相容性纳米颗粒和（ii）包含至少一种药物化合物的至少一种载体的组合，以待施用于需要这种药物化合物的受试者， 其中所述至少一种生物相容性纳米颗粒和包含所述药物化合物的所述至少一种载体的组合增强所述感兴趣的化合物效率。 生物相容性纳米粒子的最长尺寸典型地在约4和约500nm之间，并且其绝对表面电荷值至少为10mV（| 10mV |）。 另外载体没有任何表面空间稳定剂。 本发明还涉及用于在有需要的受试者中施用药物化合物的组合物，其中所述至少一种生物相容性纳米颗粒和包含所述至少一种药物化合物的所述至少一种载体分别施用 在需要所述药物化合物的受试者中，典型地在彼此之间超过5分钟至约72小时之间。

    PHARMACEUTICAL COMPOSITION, PREPARATION AND USES THEREOF
    7.
    发明公开
    PHARMACEUTICAL COMPOSITION, PREPARATION AND USES THEREOF 审中-公开
    药物组合物，制剂和用途

    公开(公告)号：EP3229781A1

    公开(公告)日：2017-10-18

    申请号：EP15800773.2

    申请日：2015-11-24

    申请人： Nanobiotix

    发明人： MEYRE, Marie-Edith ,  POTTIER, Agnès ,  LEVY, Laurent

    IPC分类号： A61K9/127 ,  A61K9/14 ,  A61K9/51 ,  A61K31/704

    CPC分类号： A61K9/127 ,  A61K9/14 ,  A61K9/51 ,  A61K31/704

    摘要： The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and of (ii) at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the nanoparticle potentiates the pharmaceutical compound efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, its absolute surface charge value is of at least 10 mV (|10 mV|), and its Young modulus is less than 100 kPa. The invention also relates to such a composition for use for administering the pharmaceutical compound in a subject in need thereof, wherein the at least one nanoparticle and the at least one pharmaceutical compound are to be administered in the subject between more than 5 minutes and about 72 hours one from each other.

    摘要翻译： 本发明涉及药物组合物，其包含（i）至少一种生物相容性纳米颗粒和（ii）至少一种药物化合物的组合，以待施用于需要这种药物化合物的受试者，其中纳米颗粒增强 药物复合效率。 生物相容性纳米粒子的最长尺寸典型地在约4nm与约500nm之间，其绝对表面电荷值为至少10mV（| 10mV |），并且其杨氏模量小于100kPa。 本发明还涉及用于在有需要的受试者中施用药物化合物的组合物，其中所述至少一种纳米颗粒和所述至少一种药物化合物将在受试者中施用超过5分钟至约72 小时彼此。

    NANOPARTICLES FOR USE IN ENHANCING BRAIN PERFORMANCES OR IN TREATING STRESS
    10.
    发明公开
    NANOPARTICLES FOR USE IN ENHANCING BRAIN PERFORMANCES OR IN TREATING STRESS 审中-公开

    公开(公告)号：EP4461363A2

    公开(公告)日：2024-11-13

    申请号：EP24202914.8

    申请日：2018-12-18

    申请人： Nanobiotix

    发明人： POTTIER, Agnès ,  LEVY, Laurent ,  MEYRE, Marie-Edith

    IPC分类号： A61P25/28

    摘要： The present invention relates to the medical field, in particular to the enhancement of brain performances and for the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ε ijk equal to or above 200, and an insulator material with a dielectric constant ε ijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof without exposure thereof to an electric field, and preferably without exposure thereof to any other external activation source such as a light source, a magnetic field, or an ultrasound source.